Everyone who knows me or has read my LinkedIn profile knows that that I am the Chairman of Team Novo Nordisk. Team Novo Nordisk is a global all-diabetes sports team of cyclists, triathletes and runners, spearheaded by the world’s first all-diabetes professional cycling team. Comprised of nearly 100 athletes from over 20 countries, Team Novo Nordisk will compete in more than 500 events worldwide in 2014.
The Team Novo Nordisk mission is to inspire, educate and empower people affected by diabetes. We ride. We run. We swim. We race to change diabetes. We strive to instill hope and inspiration for people around the world affected by diabetes. With appropriate diet, exercise, treatment and technology, we believe anyone with diabetes can pursue their dreams.
The last three weeks have clearly showed that the team is well on its way to achieve Phil Southerland’s – our founder and CEO – goal of putting an all-diabetic pro cycling team on the start line of the Tour de France by 2021, the 100th anniversary of the discovery of insulin. After a strong showing at the Tour of Turkey, Team Novo Nordisk earned its first podium finish at a major U.S. stage race and best finish of the year when second year professional Kevin De Mesmaeker sprinted to a third place finish on Stage 4 of the Amgen Tour of California last week.
Being involved with the team since 2012 has been an honour, a privilege and a great source of inspiration. I am surrounded by very meaningful and significant individuals who are on a worldwide mission to touch the lives of millions of people. The purpose of this post is to share with you a short video of an interview with Phil during the Tour of Turkey which will help you understand why Team Novo Nordisk is so dear to my heart. You will learn a lot about our leader, our riders and staff, our goals, ambitions and mission. It is only six minutes. Everyone has six minutes available to hear from someone who is dedicating his life to helping millions of people. So here we go, enjoy the video:
Please share with your friends.